Your browser doesn't support javascript.
loading
Brominated indoles from a marine mollusc inhibit inflammation in a murine model of acute lung injury.
Ahmad, Tarek B; Rudd, David; Benkendorff, Kirsten; Mahdi, Layla K; Pratt, Kaylah-Ann; Dooley, Leanne; Wei, Chuanyu; Kotiw, Michael.
Afiliación
  • Ahmad TB; Marine Ecology Research Centre, School of Environment, Science and Engineering, Southern Cross University, Lismore, NSW, Australia.
  • Rudd D; Centre for Health Sciences Research, University of Southern Queensland, Toowoomba, QLD, Australia.
  • Benkendorff K; Marine Ecology Research Centre, School of Environment, Science and Engineering, Southern Cross University, Lismore, NSW, Australia.
  • Mahdi LK; Marine Ecology Research Centre, School of Environment, Science and Engineering, Southern Cross University, Lismore, NSW, Australia.
  • Pratt KA; Centre for Health Sciences Research, University of Southern Queensland, Toowoomba, QLD, Australia.
  • Dooley L; Centre for Health Sciences Research, University of Southern Queensland, Toowoomba, QLD, Australia.
  • Wei C; Centre for Health Sciences Research, University of Southern Queensland, Toowoomba, QLD, Australia.
  • Kotiw M; Centre for Health Sciences Research, University of Southern Queensland, Toowoomba, QLD, Australia.
PLoS One ; 12(10): e0186904, 2017.
Article en En | MEDLINE | ID: mdl-29073178
New drug leads for the treatment of inflammation are urgently needed. Marine molluscs are widely used as traditional medicines for the treatment of inflammation. Here we report the positive effects of a hypobranchial gland (HBG) extract and the dominant bioactive compound 6-bromoisatin from the Muricidae mollusc Dicathais orbita, for reducing lipopolysaccharide (LPS) induced acute lung inflammation in a mouse model. Both 6-bromoisatin and the HBG extract suppressed the inflammatory response in mice that were pre-treated by oral gavage at 48, 24 and 1 h prior to LPS infusion. The inflammatory antagonists were tested at concentrations of 0.5 mg/g and 0.1 mg/g HBG extract and 0.1 mg/g and 0.05 mg/g 6-bromoisatin in carrier oil and all treatments reduced inflammation as indicated by a significant suppression of inflammatory markers present in bronchoalveolar lavage fluid (BALF), in comparison to LPS induced positive control mice administered the carrier oil alone (p < 0.0001). Tumour necrosis factor-alpha (TNFα) and interleukin-1 beta (IL-1ß) levels, in addition to total protein concentration were all significantly reduced in BALF from mice treated with the extract or 6-bromoisatin. Furthermore, all treatment groups showed significant reductions in neutrophil sequestration and preservation of the lung tissue architecture compared to the positive control (p < 0.0001). The combined results from this study and our previous in vitro studies indicate that 6-bromoisatin in the HGB extracts inhibit the activation of inflammatory signalling pathway. The results from this study further confirm that the HBG extract from Muricidae molluscs and 6-bromoisatin are bioavailable and effective in vivo, thus have potential for development as natural therapeutic agents for inflammation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bromo / Modelos Animales de Enfermedad / Lesión Pulmonar Aguda / Indoles / Inflamación / Biología Marina / Moluscos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bromo / Modelos Animales de Enfermedad / Lesión Pulmonar Aguda / Indoles / Inflamación / Biología Marina / Moluscos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos